Autoimmune hepatitis in association with ramelteon

Journal of Clinical Gastroenterology

Volumn 47, Issue 7, 2013, Pages 651-654

  Fourman, Lindsay T ^a   Robert Meyer, B ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

autoimmunity; hepatitis; melatonin; ramelteon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPRAZOLAM; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ESCITALOPRAM; F ACTIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; PREDNISONE; RAMELTEON;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; AUTOPSY; BACTERIAL PERITONITIS; BEDTIME DOSAGE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CAUSE OF DEATH; CONFUSION; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HEPATOMEGALY; HEPATOSPLENOMEGALY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN TISSUE; INSOMNIA; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; INTUBATION; LEUKOCYTE COUNT; LIQUID; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MORTALITY; NEUTROPHIL; PARACENTESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SCORING SYSTEM; STAINING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRICHOME; ULTRASOUND;

ANTI-INFLAMMATORY AGENTS; FATAL OUTCOME; HEPATITIS, AUTOIMMUNE; HUMANS; INDENES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PERITONITIS; PREDNISONE; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SLEEP INITIATION AND MAINTENANCE DISORDERS; ULTRASONOGRAPHY;

EID: 84880754025     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31829174f0     Document Type: Review

References (25)

1. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatonergic agonists. Neuropsychiatr Dis Treat. 2009;5:341-354.
2. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189-200.
3. Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007;61:835-845.
4. Makol A, Watt KD, Chowdhary VR. Autoimmune hepatitis: a review of current diagnosis and treatment. Hepat Res Treat [serial online]. 2011, Available from: http://www.hindawi.com/journals/heprt/2011/390916/. Hindawi Publishing Corporation, New York, New York. Accessed April 1, 2012.
5. Wiesner R, Edwards E, Freeman R, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
6. QUANTA Lite Actin IgG ELISA 708785. 2009;36(12). Available at: http://www.inovadx.com/PDF/nccls/708785-nccls-EN.pdf. Accessed December 15, 2012.
7. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176.
8. Navasa M, Garcia-Pagan JC, Bosch J, et al. Portal hypertension in acute liver failure. Gut. 1992;33:965-968.
9. Cohen JA, Kaplan MM. The SGOT/SGPT ratio-an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24:835-838.
10. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. New Engl J Med. 2009;360:2758-2769.
11. van de Wiel A, Schuurman HJ, Kater L. Alcoholic liver disease: an IgA-associated disorder. Scand J Gastroenterol. 1987;22:1025-1030.
12. Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol. 2010;16:6087-6097.
13. Hong YG, Riegler JL. Is melatonin associated with the development of autoimmune hepatitis? J Clin Gastroenterol. 1997;25:376-378.
14. Roy-Byrne P, Vittone BJ, Uhde TW. Alprazolam-related hepatotoxicity. Lancet. 1983;2:786-787.
15. Judd FK, Norman TR, Marriott PF. A case of alprazolamrelated hepatitis. Am J Psychiatry. 1986;143:388-389.
16. Neumann H, Csepregi A, Evert M, et al. Drug-induced liver disease related to citalopram. J Clin Psychopharmacol. 2008;28:254-255.
17. Lopez-Torres E, Lucena MI, Seoane J, et al. Hepatotoxicity related to citalopram. Am J Psychiatry. 2004;161:923-924.
18. Szczepanik M. Melatonin and its influence on immune system. J Physiol Pharmacol. 2007;58(S6):115-124.
19. European Medicines Agency. Assessment report for Circadin. 2007. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Scientific-Discussion/human/000695/WC500026808.pdf. Accessed April 1, 2012.
20. Cardinali DP, Garcia AP, Esquifino AI. Melatonin role in experimental arthritis. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:1-10.
21. Pedrosa AM, Weinlich R, Mognol GP, et al. Melatonin protects CD4+ T cells from activation-induced cell death by blocking NFAT-mediated CD95 ligand upregulation. J Immunol. 2010;184:3487-3494.
22. Liberal R, Longhi MS, Mieli-Vergani G, et al. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2011;25:653-664.
23. Liu H, Xu L, Wei JE, et al. Role of CD4+CD25+ regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. Anat Rec. 2011;294:781-788.
24. Radogna F, Paternoster L, Albertini MC, et al. Melatonin antagonizes apoptosis via receptor interaction in U937 monocytic cells. J Pineal Res. 2007;43:154-162.
25. Lardone PJ, Carillo-Vico A, Molinero P, et al. A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: signficance in IL-2 production. Cell Mol Life Sci. 2009;66:516-525.